Floatz logo

Camizestrant

ER-positive, HER2-negative Breast Cancer

AstraZenecaSmall moleculePhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the ER-positive, HER2-negative Breast Cancer cohort.

Asset / SponsorPhaseRating
[14C]AZD9833
AstraZeneca
Phase 1CC

Same molecule, other indications

Camizestrant is also rated in:

breast cancerDormant
BB
Indicative ·
68 / 100
View asset →
ER-Positive HER2-Negative Breast CancerDormant
B
Indicative ·
60 / 100
View asset →
estrogen-receptor positive breast cancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →